Objectives We aimed to assess the influence of type of operation on outcome in degenerative mitral regurgitation.
Introduction
Outcome from total valve excision and replacement for mitral regurgitation remains relatively poor, with survival rates of only 60-80% at 5 years and 40-50% at 10 years' 1 " 7 '. Mitral bioprostheses frequently fail after 7-8 years' 71 . Mechanical prostheses have greater risks of systemic thromboembolism, particularly in the mitral position, and of anticoagulation-related haemorrhage' 81 . Mitral valve repair' 9101 has reduced mortality and morbidity compared to replacement' 4 " 61 . Results are better with degenerative '"-121 than rheumatic valve disease' 13 " 161 and many now consider repair to be the operation of choice for degenerative mitral regurgitation. However, not all valves are reparable. There is concern that patients who undergo unsuccessful repair may fare worse than if they underwent valve replacement in the first instance. Clearly, we need to know the Revision submitted 9 October 1996, and accepted 16 October 1996.
Correspondence: Dr E. M. Lee, C/O Dr. Shapiro, Regional Cardiac Unit, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, U.K. risks of aggressive surgical policies favouring repair, but there is little published data on this. Postoperative myocardial failure is still a major problem because of suboptimal timing of surgery, but the optimum timing is difficult to determine. We therefore performed a study of 278 patients who underwent surgery for degenerative mitral regurgitation to assess the impact of type of operation and failed mitral valve repair on outcome and to identify prognostic indicators for clinical risk stratification.
Methods

Patients and surgery
The study group comprised 278 consecutive patients who underwent mitral valve repair (167 patients) or replacement with subvalvular preservation (MVR/SVP, 22 patients) or without subvalvular preservation (MVR/ NoSVP, 89 patients) for degenerative mitral regurgitation between 1987 and 1994. Mean age was 65-6 ±9-2 years. Mean follow-up was 38-8 ± 26-7 months. Seven 0195-668X/97/040655 + 09 S18.00/0(4-2%) patients in the repair group and one (1-2%) in the MVR/NoSVP group had incomplete follow-up. Three patients in the repair group required re-operation for recurrent mitral regurgitation within 1 year of surgery and are also included in the MVR/NoSVP group. Two patients in the MVR/NoSVP group had undergone repair 20 years previously, and 10 proceeded to MVR/ NoSVP at the same operation after unsuccessful repair. These 15 patients formed the 'failed repair' subgroup. The remainder of the MVR/NoSVP group formed the 'no repair' subgroup.
Repair was preferred to replacement. The final decision whether to attempt repair was made at operation after mitral valve inspection. The proportion of valves repaired increased from 25% in 1987 to >80% after 1990 as surgical experience increased. Techniques used were prosthetic ring annuloplasty (95-8% of repairs), sliding annuloplasty, posterior leaflet quadrangular resection, anterior leaflet wedge resection, annular or leaflet decalcification, chordal shortening and chordal transposition. Rigid Carpentier-Edwards rings were used in 89% of ring annuloplasties and Sculptor rings in 11%. Carpentier-Edwards bioprostheses were used in 25% of replacements and Bjork-Shiley and St. Jude Medical mechanical prostheses in 75%. All patients had coronary angiograms. Concomitant coronary artery bypass grafting was performed for all stenoses of > 60% diameter in large arteries and aortic valve replacement for all haemodynamically significant aortic valve disease. Levels of medical, surgical and anaesthetic experience (except with mitral valve repair), myocardial protection techniques (cold cardioplegia only, no coronary perfusion techniques) and patient selection criteria for surgery were constant during the study period.
Postoperative care
All patients were anticoagulated with warfarin postoperatively. Anticoagulation in patients in sinus rhythm was stopped 3 months after repair or bioprosthetic MVR unless other indications were present. The remaining patients were anticoagulated long-term. The target international normalized ratio was 3 0-4-0 in patients with and 2 0 -3 0 in patients without mechanical valve prostheses. All patients were routinely maintained on frusemide 40 mg and amiloride 5 mg daily. Higher doses of diuretics and angiotensin converting enzyme inhibitors were started only when overt heart failure developed.
Left ventricular and mitral valve function
Left ventricular ejection fraction was estimated by echoeardiography and angiography pre-operatively and by echoeardiography postoperatively, using visual estimation and the Hewlett-Packard Sonos 1500 internal analysis package to calculate the echocardiograms. Mitral regurgitation was graded from 0 (none) to 4 (severe) by pulsed wave Doppler' 171 . All patients had grade 3 or 4 mitral regurgitation pre-operatively. Mitral valve areas following valve repair were measured by continuous wave Doppler using the pressure half-time method" 81 .
Statistical methods
The end-point in survival analysis was the first episode of each complication. The guidelines' 19 
Results
Baseline characteristics
The repair group differed from the MVR/SVP and MVR/NoSVP groups, with more posterior and less anterior mitral valve leaflet pathology, longer ischaemic operation times, less ischaemic heart disease and more patients in NYHA class III or IV pre-operatively. There Eur Heart J, Vol. 18, April 1997 LVEF=left ventricular ejection fraction, NYHA = New York Heart Association. The P values are for comparison with the MVR/NoSVP group, "operation notes were unclear regarding leaflet involvement. LVEF=left ventricular ejection fraction, NYHA = New York Heart Association, "operation notes were unclear regarding leaflet involvement.
were no significant differences between the MVR/SVP and MVR/NoSVP groups. The 'failed repair' MVR/ NoSVP subgroup had longer ischaemic operation times than the 'no repair' subgroup. Baseline patient characteristics are shown in Tables 1 and 2 .
Mortality
Mortality was lower with repair and MVR/SVP than with MVR/NoSVP. Although most differences did not reach statistical significance on univariate analysis, they were significant on multivariate analysis. Thirty-day mortality was 1 -2% (ns) vs 00% (ns) vs 4-5%, respectively. Six-year survival was 67-8 ±7-4% (7>=0-082) vs 80-8 ± 1 1 0 % (P=0-25) vs 63-3 ± 5-9% for all-cause death, 78-5±6-8% (/>=0063) vs 95-5 ±4-4% (^=0092) vs 67-6 ± 5-9% for complication-related death, 80-5 ±6-9% (/>=0076) vs 1000 ± 0 0 % (7>=0-045) vs 72-8 ± 5-8% for death due to myocardial failure and 97-5 ±1-2% (/ > =0-22) vs 95-5 ±4-4% (7>=0-75) vs 89-9 ± 3-7% for death due to other complications respectively (Fig. 1) . effects of repair compared to MVR/NoSVP on complication-related death (hazard ratio 0-42, P=0-0\0) and death due to myocardial failure (hazard ratio 0-40, P=00\4). Risk factors for complication-related death and death due to myocardial failure were age >70 years, pre-operative left ventricular ejection fraction (<40% and NYHA class III or IV symptoms (Table 4) .
Myocardial failure
Six-year cumulative freedom from myocardial failure in the repair, MVR/SVP and MVR/NoSVP subgroups was 60-7 ± 8-6% (ns) vs 680 ± 14-7% (ns) vs 58-3 ± 6-5%, respectively (Fig. 2) . On multivariate analysis, preoperative NYHA class and left ventricular ejection fraction <40% were significant predictors of postoperative myocardial failure, but type of operation was not (Table 4) . Functional results were good with 91-3% (ns) vs 83-3% (ns) vs 91-8% of survivors in the repair, MVR/SVP and MVR/NoSVP groups respectively in NYHA class I or II at follow-up.
Other complications
Six-year complication-free survival in the repair, MVR/ SVP and MVR/NoSVP groups was 9 8 0 ± 11% (ns) vs 100-0±00% (ns) vs 98-7 ±1-3% for endocarditis, 85-4 ±3-5% (ns) vs 1000 ± 0 0 % (ns) vs 77-3 ± 5-4% for systemic thromboembolism, 98-2 ± 1 1 % (ns) vs 88-1 ±8-2% (ns) vs 88-2 ±4-4% for anticoagulationrelated haemorrhage and 96-2 ±1-5% (ns) vs 1000 ± 0-0% (ns) vs 95-5 ± 2-6% for mitral valve failure, respectively (Fig. 2) . Complications are summarized in Table 3 . Multivariate analysis showed independent beneficial effects from repair compared to mechanical replacement (hazard ratio 0-45, />=0029, for thromboembolism and hazard ratio 019, P=0-026, for anticoagulation-related haemorrhage, Table 4 ). 
Outcome in MVR subgroups
There were no significant differences in mortality or complications of myocardial failure in the 'failed repair' and 'no repair' subgroups. Thirty day mortality was 6-7% (one patient) vs 4-2% (three patients, ns) respectively. Cumulative freedom at 6 years from all-cause death was 73-2 ±14-0% vs 61-5 ± 6-6% (ns), from complication-related death 73-2 ± 14-0% vs 68-8 ± 6-5% (ns), and from death due to myocardial failure was 73-2 ± 140% vs 740 ± 6-4% (ns), respectively.
Discussion
The superiority of mitral valve repair to replacement
Degenerative valve disease is the commonest cause of severe mitral regurgitation in developed nations and accounted for >60% of operations for mitral regurgitation during the study period. Myocardial failure is the predominant postoperative problem. It caused >75% of complication-related deaths; 6-year mortality from myocardial failure was 20% and 6-year freedom from myocardial failure was only 60%. Preservation of left ventricular function is clearly of paramount importance and has been shown to be better in repair than MVR/NoSVP in both experimental' 
Complications following mitral valve repair
Outcome from mitral valve repair with respect to mitral valve failure, endocarditis, and anticoagulation-related haemorrhage was excellent with 6-year complication rates of < 2% each. The relatively high rate of systemic thromboembolism (14-7% at 6 years) could be explained by the presence of multiple risk factors unrelated to repair. Apart from an abnormal mitral valve, >50% of our patients had chronic atrial fibrillation, >90% had left atrial enlargement 1301 , >35% had clinical heart failure and/or significant left ventricular impairment echocardiography, >50% were >65 years old at operation and 20% had pre-existing coronary, cerebrovascular or peripheral vascular disease. Risks of thromboembolism in warfarinised non-rheumatic atrial fibrillation range from 2% per year overall to 7%-17% per year in patients with multiple other clinical or echocardiographic risk factors' 31 '. Our results are consistent with these estimated risks.
The need for early surgery
Repair only reduced the severity of, and hence the mortality from, myocardial failure. It did not affect the overall incidence of postoperative myocardial failure which was high in all groups, probably because the main contributing factor is pre-existing irreversible left ventricular impairment. NYHA class III or IV symptoms are useful markers of left ventricular impairment in severe mitral regurgitation, particularly as the regurgitation masks the decline in left ventricular contractility and ejection fraction. The risk of postoperative myocardial failure is markedly increased by pre-operative NYHA class III or IV symptoms (hazard ratio 6-6) and a left ventricular ejection fraction of <40% (hazard ratio 4-8). Early surgery before these features appear is essential to optimise outcome. Unfortunately, >65% of our patients were in NYHA class III or IV and 20% had left ventricular ejection fractions of <40% preoperatively. Until the problem of suboptimal timing of surgery is overcome, myocardial failure is likely to remain a major postoperative problem.
The influence of age on outcome
Age >70 years was not an independent predictor of postoperative myocardial failure, but myocardial failure was significantly more likely to be fatal in this age group (hazard ratio 2-5). The reason for this is unclear. NYHA classification is based on clinical history, not exercise tests. It is a subjective, broad and imprecise classification and may be systematically underestimated in the elderly because of lower expectations, more sedentary lifestyles and a slower pace of life, resulting in delayed presentation or delayed referral for surgery. The elderly may have had more severe left ventricular dysfunction than younger patients in the same NYHA class. General frailty may also reduce the tolerance of the elderly to myocardial failure and contribute to the higher mortality.
Surgery in patients with irreparable mitral valves
The rate of unsuccessful repair has been underestimated in most studies of mitral valve repair as patients who underwent failed repair and proceeded to replacement at the same operation were not reported. In our study, repair failed in 15 (7-3%) patients who required valve replacement at the same operation or at re-operation for residual or recurrent mitral regurgitation. An aggressive policy favouring repair could theoretically worsen outcome in such patients. Ischaemic time is longer, reoperation may be needed and complexity of surgery increased. However, we found no significant difference in mortality or myocardial failure between patients who required valve replacement following unsuccessful repairs and those who underwent MVR in the first instance.
The proportion of patients with irreparable valves has not been formally studied, although it has been estimated at <10% for non-rheumatic mitral valve disease 1321 . Our rate of repair rose with increasing experience from 25% to >80% within 5 years. The indications have extended from uncomplicated posterior leaflet prolapse and/or annular dilatation to include complicated lesions of either or both leaflets and annular calcification. The introduction of artificial chordae may further increase the rate of repair. Nevertheless, it is likely that a significant proportion of valves, perhaps 10%, will remain irreparable because of severe disorganisation of the valve or further degeneration following repair leading to recurrent mitral regurgitation.
It has been suggested that if repair is not feasible, then the increased rates of thromboembolism and haemorrhage associated with mechanical prostheses may obviate the benefits of early surgery and constitute sufficient reason to delay surgery 1331 , particularly in patients aged <70 years in whom bioprostheses are unsuitable because of low durability 171 . However, this may not be true. The chief cause of mortality and morbidity after surgery for mitral regurgitation is myocardial failure. The highest priority should therefore be preservation of left ventricular function, and early surgery with subvalvular preservation is required to achieve this. Complicated repairs can now be performed successfully and it is often difficult to predict pre-operatively whether a diseased mitral valve is reparable or not. 
The influence of concomitant ischaemic heart disease
The lack of influence of ischaemic heart disease on outcome in our study may be explained by a number of factors. Concomitant bypass surgery was performed in all patients with significant coronary artery disease.
Bypass graft failure mainly occurs late, outside the time frame of our study. This may explain the low incidence of postoperative myocardial infarction or ischaemia. One major reason for poor outcome with ischaemic heart disease with mitral regurgitation is its association with poor pre-operative left ventricular function. Since continued ischaemia was prevented by coronary artery bypass grafting and left ventricular function accounted for in the multivariate analysis, ischaemic heart disease itself had no independent effect on outcome.
pre-existing left ventricular impairment. Pre-operative NYHA class III or IV heart failure and left ventricular ejection fraction of <40% are major independent predictors of postoperative myocardial failure. Early surgery prior to the development of these features is also needed to optimise outcome.
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Limitations and confounding factors
Our study was limited by lack of randomization and its retrospective nature. Despite multivariate analysis, which is an established method of accounting for baseline group differences, observational studies have been criticised for the lack of comparability between patient groups. It has been suggested that irreparable mitral valve disease may differ from reparable disease and have independent deleterious effects leading to worse outcome with valve replacement. However, outcomes were similar in the MVR/NoSVP subgroup who underwent surgery in 1987-1988, 75% of whom would have had repair if the level of surgical experience in valve repair had been higher, and the subgroup who underwent surgery in 1993-1994, almost all of whom had irreparable valves. The main reason for valve replacement rather than repair was major anterior leaflet pathology as anterior leaflet repair is more difficult. The affected leaflet was not a significant prognostic indicator on multivariate analysis. Furthermore, MVR/SVP was also performed in patients with irreparable valves and showed trends towards better outcome than with MVR/ NoSVP, although trends were not significant because of small patients numbers. Valve irreparabililty is unlikely to be a significant independent risk factor and the differences attributed to type of operation are likely to be genuine.
Our MVR/SVP group was too small to demonstrate significant benefits of subvalvular preservation in mitral valve replacement although the trends towards better results are consistent with other studies. The apparent superiority of MVR/SVP to repair in our study also had no statistical significance. Larger studies are required to resolve these issues. Similarly, there were too few patients with bioprosthesis to demonstrate significant effects on outcome.
Conclusion
Outcome from mitral valve repair for degenerative mitral regurgitation is superior to replacement without subvalvular preservation. Repair should therefore be the operation of choice whenever feasible. However, although repair reduces the severity and hence the mortality from myocardial failure, the overall rate of myocardial failure remains high, as a consequence of
